Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonas S Heitmann

Showing results (21-30 of 66) with videos related to

Pageof 7
Sort By:
BMC Cancer|June 6, 2026
B7-H3 membranous expression correlates with histological grading in a two-center cohort of 133 pre-treatment bone and soft tissue sarcoma samplesLinus D Kloker, Robert Rottscholl, Jonas S Heitmann, et al.
Diagnostics (Basel, Switzerland)|November 27, 2021
Immunoprofiling of 4-1BB Expression Predicts Outcome in Chronic Lymphocytic Leukemia (CLL)Kübra Kaban, Sarah M Greiner, Samuel Holzmayer, et al.
Cancers|December 11, 2019
Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 AntibodyBastian J Schmied, Martina S Lutz, Fabian Riegg, et al.
Cancers|December 10, 2021
Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease CourseKim L Clar, Lisa M Weber, Bastian J Schmied, et al.
Journal for Immunotherapy of Cancer|February 3, 2022
Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodiesMartina Svenja Lutz, Boris Klimovich, Stefanie Maurer, et al.
Diagnostics (Basel, Switzerland)|July 2, 2021
Regulation of Platelet-Derived ADAM17: A Biomarker Approach for Breast Cancer?Yanjun Zhou, Jonas S Heitmann, Korbinian N Kropp, et al.
Journal of Leukocyte Biology|April 18, 2020
A novel flow cytometry-based assay to measure compromised B cell receptor signaling as a prognostic factor in chronic lymphocytic leukemiaJonas S Heitmann, Melanie Märklin, Felicia M Truckenmüller, et al.
Cancers|April 30, 2021
An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic LeukemiaFabian Riegg, Martina S Lutz, Bastian J Schmied, et al.
Journal for Immunotherapy of Cancer|June 1, 2020
Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodiesJoseph Kauer, Sebastian Hörner, Lukas Osburg, et al.
Journal of Visualized Experiments : Jove|December 25, 2018
A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic LeukemiaAlexander R Fuchs, Melanie Märklin, Jonas S Heitmann, et al.
Pageof 7

Showing results (21-30 of 66) with videos related to

Sort By:
Pageof 7
BMC Cancer|June 6, 2026
B7-H3 membranous expression correlates with histological grading in a two-center cohort of 133 pre-treatment bone and soft tissue sarcoma samplesLinus D Kloker, Robert Rottscholl, Jonas S Heitmann, et al.
Diagnostics (Basel, Switzerland)|November 27, 2021
Immunoprofiling of 4-1BB Expression Predicts Outcome in Chronic Lymphocytic Leukemia (CLL)Kübra Kaban, Sarah M Greiner, Samuel Holzmayer, et al.
Cancers|December 11, 2019
Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 AntibodyBastian J Schmied, Martina S Lutz, Fabian Riegg, et al.
Cancers|December 10, 2021
Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease CourseKim L Clar, Lisa M Weber, Bastian J Schmied, et al.
Journal for Immunotherapy of Cancer|February 3, 2022
Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodiesMartina Svenja Lutz, Boris Klimovich, Stefanie Maurer, et al.
Diagnostics (Basel, Switzerland)|July 2, 2021
Regulation of Platelet-Derived ADAM17: A Biomarker Approach for Breast Cancer?Yanjun Zhou, Jonas S Heitmann, Korbinian N Kropp, et al.
Journal of Leukocyte Biology|April 18, 2020
A novel flow cytometry-based assay to measure compromised B cell receptor signaling as a prognostic factor in chronic lymphocytic leukemiaJonas S Heitmann, Melanie Märklin, Felicia M Truckenmüller, et al.
Cancers|April 30, 2021
An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic LeukemiaFabian Riegg, Martina S Lutz, Bastian J Schmied, et al.
Journal for Immunotherapy of Cancer|June 1, 2020
Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodiesJoseph Kauer, Sebastian Hörner, Lukas Osburg, et al.
Journal of Visualized Experiments : Jove|December 25, 2018
A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic LeukemiaAlexander R Fuchs, Melanie Märklin, Jonas S Heitmann, et al.
Pageof 7